Non‐progression of HIV infection 20 years after diagnosis

Lefrère, Jean‐Jacques; Morand‐Joubert, Laurence

doi:10.1111/j.1537-2995.2004.00354.x

Cited by 2 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These patients were selected from the HIV-1-infected patient cohort of the St-Antoine Hospital (Paris), and the samples were collected with written informed consent [45], [46]. The graphs show the time-course evolution of the blood CD4+ T cell counts (green curves) and plasmatic virus load (viral RNA, red curves); the PBMC samples analyzed in the present study are indicated by the blue arrows.…”

Section: Resultsmentioning

confidence: 99%

“…The LTNP patient was still asymptomatic 22 years after contamination, in the absence of antiretroviral therapy, with relatively stable CD4 cell counts (>350 cells/mm3) and low levels of viral RNA for the first 10 years of infection. From 2000 to 2006, we observed an increase in the copy number of viral RNA followed by a decrease in the CD4 cell-count [45], [46]. Three samples of frozen peripheral blood mononuclear cells (PBMC) at different time points (1986, 1996, 2004, 2005 and 2006) were analyzed.…”

Section: Methodsmentioning

confidence: 99%

“…Conversely, the progressor patient was infected in 1985 and rapidly treated by ZDV on the basis of a low level of CD4+ T lymphocytes (<200 cells/mm3); the PBMC sample analyzed herein was isolated in 1988, 2 years before the patient died of AIDS. All the blood samples were collected in a previous longitudinal study, approved by the ethics committee from the St-Antoine Hospital (Paris, France), with written informed consent from infected patients [45], [46].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Characterization of the Molecular Determinants of Primary HIV-1 Vpr Proteins: Impact of the Q65R and R77Q Substitutions on Vpr Functions

et al. 2009

Self Cite

View full text Add to dashboard Cite

Although HIV-1 Vpr displays several functions in vitro, limited information exists concerning their relevance during infection. Here, we characterized Vpr variants isolated from a rapid and a long-term non-progressor (LTNP). Interestingly, vpr alleles isolated from longitudinal samples of the LTNP revealed a dominant sequence that subsequently led to diversity similar to that observed in the progressor patient. Most of primary Vpr proteins accumulated at the nuclear envelope and interacted with host-cell partners of Vpr. They displayed cytostatic and proapoptotic activities, although a LTNP allele, harboring the Q65R substitution, failed to bind the DCAF1 subunit of the Cul4a/DDB1 E3 ligase and was inactive. This Q65R substitution correlated with impairment of Vpr docking at the nuclear envelope, raising the possibility of a functional link between this property and the Vpr cytostatic activity. In contradiction with published results, the R77Q substitution, found in LTNP alleles, did not influence Vpr proapoptotic activity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of the Molecular Determinants of Primary HIV-1 Vpr Proteins: Impact of the Q65R and R77Q Substitutions on Vpr Functions

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…Conservatively, if C122 was downgraded to slow progressor status, this still gives 5 of 137 (3.6%) true LTNPs after 20 years. Additionally, if we were to eliminate the SBBC bias of an attenuated HIV‐1 strain, removal of all recipients of the SBBC donor leaves 2 of 128 (1.6%) true LTNPs after 20 years of infection, which is still a higher LTNP proportion than the cohort of Lefrère and colleagues 3 . Like Lefrère's study group, however, our LTNP cohort is dwindling.…”

mentioning

confidence: 85%

“…They had 21 from a cohort of 249 classified as LTNPs according to earlier definitions, but after a strict examination of all signs of disease progression, including virologic parameters, only two could be classed as true nonprogressors. We were therefore interested in a recent update from this group 3 showing that only one individual remained asymptomatic and antiretroviral naïve after 20 years infection, yet was now showing signs of disease progression.…”

mentioning

confidence: 99%

High frequency of nonprogression 20 years after transfusion‐transmitted human immunodeficiency virus type‐1 infection

Dyer¹,

Learmont

Geczy

et al. 2004

Transfusion

View full text Add to dashboard Cite

Each year approximately 3 million units of fresh frozen plasma (FFP) are transfused in the US. FFP transfusions risk several complications including volume overload, allergic reactions, acute lung injury, and transmission of infectious pathogens. Most consensus guidelines list only a few clear indications for transfusion of FFP including treatment of bleeding due to multiple factor deficiencies, emergency reversal of vitamin K antagonists, and treatment of thrombotic thrombocytopenic purpura (TTP). 1 These limited indications would not appear to account for the widespread use of FFP and published audits of FFP transfusion have frequently suggested inappropriate usage. 2 Nevertheless, most published audits report indications as interpreted by chart review of transfusions given, rather than indications as stated by the prescribing physician before the FFP is administered.Massachusetts General Hospital (MGH) uses a computerized system for physician order entry (POE) for all transfusions given outside of the operating rooms. This software requires that the individual ordering a transfusion select from a "pick list" to declare the reason for the transfusion. The software is used for all requests on both adult and pediatric services except those originating in the operating rooms and those originating within the transfusion service for the treatment of TTP by plasma exchange. Requesting physicians can select "other" for cases not meeting one of the pick list entries. We report in Table 1 the reasons stated by prescribing physicians for all FFP transfusions requested at the hospital using POE during the period from February through April 2003. Of note, the most common reason for prescribing FFP was to "prepare" a patient with an elevated international normalized ratio (INR) for an invasive procedure. This single "indication" represents one-third of all plasma requested by the physicians with POE.MGH performs blood utilization review of all transfusions given outside the operating room. Electronic mail feedback is given to the ordering physician within 24 hour following the transfusion. Because review before blood release is not done, POE requests are generally filled as requested. Although our data are intended to reflect the reasons why physicians request FFP (rather than report on FFP transfused), the POE data presented in Table 1 represent a substantial proportion of FFP transactions. For example, during the period from February to April 2003 the total number of transfused products at MGH (both operating room and non-operating room) was 3636 units of FFP, 8988 units of red blood cells, and 3219 units other components.There is little published evidence to support the use of FFP transfusion as an appropriate prophylaxis before invasive procedures. In fact, published retrospective studies examining the ability of the prothrombin time or INR to predict bleeding at the time of invasive procedures have failed to demonstrate a correlation between the INR and hemorrhagic outcomes. 3-5 Likewise we could find no published evid...

show abstract

Non‐progression of HIV infection 20 years after diagnosis

Cited by 2 publications

References 5 publications

Characterization of the Molecular Determinants of Primary HIV-1 Vpr Proteins: Impact of the Q65R and R77Q Substitutions on Vpr Functions

Characterization of the Molecular Determinants of Primary HIV-1 Vpr Proteins: Impact of the Q65R and R77Q Substitutions on Vpr Functions

High frequency of nonprogression 20 years after transfusion‐transmitted human immunodeficiency virus type‐1 infection

Contact Info

Product

Resources

About